Ono Pharmaceutical Co., Ltd. (ON4.F)

12,80 +0,20 (+1,59%) A partir del 03:29PM CEST. Mercado abierto.

Ono Pharmaceutical Co., Ltd.

8-2, Kyutaromachi 1-chome
Chuo-ku
Osaka 541-8564
Japan
81 6 6263 5670
https://www.ono-pharma.com

Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Gyo Sagara	CEO & Chairman of the Board	799,37k	N/A	1958
Mr. Toichi Takino Ph.D.	President, COO & Representative Director	N/A	N/A	1968
Mr. Masaki Ito	Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. Tax	N/A	N/A	N/A
Takehiro Yamada	Corporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion Office	N/A	N/A	N/A
Masayuki Tanigawa	Corporate Officer & Executive Director of Corporate Development & Strategy	N/A	N/A	N/A
Mr. Toshihiro Tsujinaka	Ex. EO, Executive Dir. of Sus. Promotion Corp. Strategy & Planning and Representative Director	N/A	N/A	1964
Hiromu Habashita Ph.D.	Corporate Officer & Deputy Executive Director, Discovery & Research	N/A	N/A	N/A
Shinji Takai M.D., Ph.D.	Corporate Officer & Head of Medical Affairs	N/A	N/A	N/A
Satoshi Takahagi	Corporate Officer and Executive Director of Sales, Marketing & Primary Care Business Division	N/A	N/A	N/A
Akira Takada	Corporate Officer and Executive Director of CMC & Production	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Gobierno corporativo

El ISS Governance QualityScore de Ono Pharmaceutical Co., Ltd., a día 1 de junio de 2024, es 2. Las puntuaciones base son Auditoría: 1; Tablero: 3; Derechos de los accionistas: 2; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.